Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q1 2024 · 10-Q
Revenue$144.92M$144.92M+0.1% vs Q1 2023 Net Income$27.71M$27.71MN/M vs Q1 2023 EPS Diluted$0.71$0.71N/M vs Q1 2023 Gross Profit$91,456,000+18.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flow$61,937,000+123.8% Free Cash Flowderived$61,369,000+123.2% Margins · derivedGross margin63.1%+9.6 pt vs Q1 2023
Operating margin34.1%+17.1 pt vs Q1 2023
Net margin19.1%+31.2 pt vs Q1 2023
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end